Research

A 2026 analysis of randomized LISA trial data reported lower brain-age-gap scores after moderate and heavy resistance training; the score is not a clinical outcome.

Evidence verdict: Partial cellular reprogramming remains unproven as a general anti-aging therapy. ER-100, an AAV2-OSK candidate, has begun Phase 1 safety testing for glaucoma and non-arteritic anterior ischemic optic neuropathy; the first participant was dosed in June 2026. That disease-specific study is an important translational milestone, not evidence…

Evidence verdict: Taurine is now being tested in randomized human studies that include biological-age, metabolic and physical-function endpoints. The completed TauAge record used 4 g/day for six months and enrolled 90 adults aged 55–75, but no results are posted. A 2026 phase II protocol uses 3 g/day and…

A Lothian Birth Cohort analysis linked reported gardening frequency with aging measures and mortality, but its observational design cannot show that gardening causes longer life.

Evidence verdict: In the NIA Interventions Testing Program, alpha-ketoglutarate did not significantly increase lifespan in male or female genetically heterogeneous UM-HET3 mice. Because the ITP is multi-site and designed to replicate lifespan effects, this materially weakens broad claims that AKG is an established lifespan-extending supplement. It does not…

A 2026 UK Biobank study linked severe sleep restriction without rebound sleep to higher all-cause mortality, but its observational design cannot show that rebound sleep prevents deaths.

A 2026 study used post-mortem tissue images to model tissue-specific age patterns. Here is what the clocks measured, how they were validated, and why they are not personal clinical tests.

Evidence verdict: Proteomic aging clocks are becoming more interpretable and externally tested. Large 2025–2026 studies show that organ- and cell-specific protein signatures predict disease and mortality beyond chronological age in selected cohorts. A lower proteomic age is not the literal age of a person or organ, and no…

Evidence verdict: In a prespecified two-year COSMOS ancillary study, daily multivitamin–multimineral supplementation modestly reduced the yearly increase in PCGrimAge and PCPhenoAge versus placebo. Cocoa extract did not significantly affect the five tested clocks. The differences were small and do not show that multivitamins reverse aging, prevent disease through…

Evidence verdict: The 2026 TranslAGE analysis is meaningful progress for trial design. Mortality- and pace-of-aging-oriented clocks were generally more responsive than first-generation chronological-age clocks, while pharmacological and lifestyle interventions showed stronger biomarker responses than several other categories. But responsiveness alone does not prove that changing a clock causes…